DOCSLIB.ORG

China's Biotechnology Development: the Role of US and Other Foreign

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
China's Biotechnology Development: the Role of US and Other Foreign China’s Biotechnology Development: The Role of US and Other Foreign Engagement A report prepared for the U.S.-China Economic and Security Review Commission February 14, 2019 Gryphon Scientific, LLC Rhodium Group, LLC 6930 Carroll Avenue, Suite 810 5 Columbus Circle Takoma Park, Maryland 20912 New York, NY 10019 Mark Kazmierczak, Ph.D. Thilo Hanemann Ryan Ritterson, Ph.D. Daniel H. Rosen Danielle Gardner Rocco Casagrande, Ph.D. [email protected] [email protected] [email protected] [email protected] 301-270-0374 212-247-3997 Disclaimer: This research report was prepared at the request of the U.S.-China Economic and Security Review Commission to support its deliberations. Posting of the report to the Commission's website is intended to promote greater public understanding of the issues addressed by the Commission in its ongoing assessment of U.S.-China economic relations and their implications for U.S. security, as mandated by Public Law 106-398 and Public Law 113-291. However, it does not necessarily imply an endorsement by the Commission or any individual Commissioner of the views or conclusions expressed in this commissioned research report US Role in China’s Biotechnology Development CONTENTS Executive Summary 2 Introduction 9 1. China’s Biotechnology Sector 12 1.1. Current State of China’s Biotechnology Industry by Segment ....................................................... 13 The Biotechnology Market at a Glance .................................................................................. 13 Biologics (Biopharmaceuticals) .............................................................................................. 15 Genomics, Molecular Diagnostics, and Precision Medicine ................................................... 25 Agricultural Biotechnology ...................................................................................................... 27 Industrial Biotechnology ......................................................................................................... 33 1.2. China’s Plans and Goals for Biotechnology ................................................................................... 35 China’s Science and Technology Programs .......................................................................... 35 The Strategic Emerging Industries Initiative ........................................................................... 36 The 12th and 13th Five-Year Plans .......................................................................................... 36 Made in China 2025 ............................................................................................................... 38 Talent Programs ..................................................................................................................... 38 Biotechnology Parks ............................................................................................................... 39 Local level Policies ................................................................................................................. 40 1.3. Comparison of Chinese and US Biotechnology Programs ............................................................. 41 Comparison of Industrial Policies ........................................................................................... 41 Comparison of Biotechnology Spending ................................................................................ 41 1.4. Outlook ............................................................................................................................................ 42 2. The Role of Foreign Firms and Technologies in China’s Biotechnology Development 45 2.1. Foreign Investment in China ........................................................................................................... 46 Direct Investment .................................................................................................................... 46 Venture Capital and Other Portfolio Investment ..................................................................... 49 Overseas Listings ................................................................................................................... 53 2.2. Chinese Outbound Investment ....................................................................................................... 55 Direct Investment .................................................................................................................... 55 Venture Capital and Other Portfolio Investment ..................................................................... 59 2.3. Other Channels ............................................................................................................................... 62 Patent Acquisitions and Licensing .......................................................................................... 62 Research Partnerships and other Collaborations ................................................................... 63 Overseas Scientists ................................................................................................................ 66 2.4. Espionage and Other Illicit Activities ............................................................................................... 68 2.5. Regulatory Supervision of Foreign Interaction with Chinese Biotech Firms and Individuals ......... 71 3. Chinese Investment in the US Biotechnology Industry 73 3.1. Annual Flows and Stock ................................................................................................................. 74 3.2. Entry Mode ...................................................................................................................................... 76 3.3. Investor Mix ..................................................................................................................................... 77 3.4. By Segments ................................................................................................................................... 80 Biologics ................................................................................................................................. 82 Contract Research or Manufacturing...................................................................................... 85 Genomics and Related Technologies .................................................................................... 87 Molecular Diagnostics and Precision Medicine ...................................................................... 89 Research/Discovery Platforms, Tools and Support Products ................................................ 91 i US Role in China’s Biotechnology Development Industrial Bioproduction and Bioprocessing ........................................................................... 92 Agricultural or Agriculture-Applicable Biotechnology .............................................................. 94 Biotech Incubators/Accelerators ............................................................................................. 96 3.5. US Regulation of Foreign Investment ............................................................................................. 97 3.6. Outlook .......................................................................................................................................... 100 4. China’s Involvement in U.S.-Based Research Organizations 103 4.1. Types of Partnerships ................................................................................................................... 103 Research and Development Centers ................................................................................... 104 Biotechnology Incubators ..................................................................................................... 105 Other partnerships ................................................................................................................ 106 4.2. Chinese Students and Academic Research in the US ................................................................. 107 China’s Talent Programs ...................................................................................................... 107 University partnerships ......................................................................................................... 109 4.3. Benefits and Risks ........................................................................................................................ 110 Role of U.S. government in regulating international research .............................................. 112 5. China’s Access to U.S. Healthcare-Related Data 115 5.1. Healthcare Data and Biotechnology ............................................................................................. 115 Genomic Data ....................................................................................................................... 116 5.2. China’s Investments in Modernizing Collection of Healthcare Data ............................................. 117 China’s Improvements in Data Infrastructure ....................................................................... 119 5.3. Channels of Access to US Healthcare Data ................................................................................. 120 Chinese Investment in US Healthcare Data Companies ..................................................... 120 Chinese-US Partnerships ....................................................................................................
Load more

Recommended publications
  • A Chinese Pharmaceutical Startup Acquires an American Firm to “Go Global”
    Paulson Papers on Investment Case Study Series A Chinese Pharmaceutical Startup Acquires an American Firm to “Go Global” June 2016 Paulson Papers on Investment Case Study Series Preface or decades, bilateral investment manufacturing—to identify tangible has flowed predominantly from the opportunities, examine constraints and FUnited States to China. But Chinese obstacles, and ultimately fashion sensible investments in the United States have investment models. expanded considerably in recent years, and this proliferation of direct investments Most of the case studies in this Investment has, in turn, sparked new debates about series look ahead. For example, our the future of US-China economic relations. agribusiness papers examine trends in the global food system and specific US and Unlike bond holdings, which can be Chinese comparative advantages. They bought or sold through a quick paper propose prospective investment models. transaction, direct investments involve people, plants, and other assets. They are But even as we look ahead, we also a vote of confidence in another country’s aim to look backward, drawing lessons economic system since they take time from past successes and failures. And both to establish and unwind. that is the purpose of the case studies, as distinct from the other papers in this The Paulson Papers on Investment aim series. Some Chinese investments in to look at the underlying economics— the United States have succeeded. They and politics—of these cross-border created or saved jobs, or have proved investments between the United States beneficial in other ways. Other Chinese and China. investments have failed: revenue sank, companies shed jobs, and, in some Many observers debate the economic, cases, businesses closed.
    [Show full text]
  • BGI at a Glance EN20190626
    AT A GLANCE BACKGROUND The Human Genome Project (HGP) is considered one of the greatest scientific achievements of the last century. BGI was founded in 1999 in order to participate in this significant research project. Since then, BGI has become a world-leading life science organization. SERVICES BGI leads innovative development in genom- ics and life sciences through its integrated model incorporating industry development, ed- ucation and research in compliance with inter- national bioethical protocols, and applies fron- tier multi-omics research findings to areas in- cluding medicine, healthcare, resource con- servation, forensics and more; and provides cutting-edge proprietary life science instruments and devices, technical support and solutions to accelerate industry transfer of genomic technologies and revolu- tionize current healthcare system towards precision medicine and precision healthcare, using "omics" to benefit the mankind. CORE CAPABILITIES Research BGI·Research 24 2200+ 1200+ Innovation Centers SCI Publications Patent Applications (including 1 national and 7 provincial) Sequencing Services BGI·Genomics Reproductive Health Cancer Prevention Infectious Diseases and Treatment Advanced Tools in Life Sciences MGI Fully automated scale data production Oct. 2018: launched the ultra-high-throughput sequencer MGISEQ-T7 and the high-throughput automated sample preparation system MGISP-960 Oct. 2017: launched high-throughput genetic sequencers MGISEQ-2000 and MGISEQ-200, MGIFLP modular NGS workstation，and MGI- US-R3 robotic ultrasound system Nov. 2016: launched the BGISEQ-50 desktop sequencing system Oct. 2015: launched the BGISEQ-500 high-throughput desktop sequencing system Jun. 2015: launched the RevolocityTM sequencing system Jul. 2014: launched the BGISEQ-1000 sequencing system Mar. 2013: successful acquisition of a U.S.
    [Show full text]
  • Our 5 Columbus Circle Center Is Located Within Blocks from Central Park, Carnegie Hall and Time Warner Center
    Our 5 Columbus Circle Center is located within blocks from Central Park, Carnegie Hall and Time Warner Center. The center is also within one block from the N, Q, R W, A, C, B, D and 1 subway lines. It is a five minute walk to E subway line. Our Center boasts an extraordinary, sophisticated and luxurious collection of original artwork and spectacular views of Columbus Circle. It is a minute walk to the renown Central Park. The 5 Columbus Circle has 30 fully furnished and wired offices, two conference rooms, and a large pantry / break room serving freshly brewed Starbucks Coffee and a continental breakfast every morning. All of Bevmax’s offices are equipped with state-of-the art telephone and high-speed internet access. Bevmax makes it easy for you to be in your new office, complete with telephone, Internet, secretarial, receptionist, mail and conference room services, allowing you to concentrate on your business! ! Our 5 Columbus Circle is located within blocks from Central Park, Carnegie Hall, and Time Warner Center. The center is also within one block from the N, Q, R, W, A, C, B, D and 1 subway lines. It is a five minute walk to E subway line. Our Center boasts an extraordinary, sophisticated and luxurious collection of original artwork and spectacular views of Columbus Circle. It is a minute 485 Madison Avenue walk to the renown Central Park. 7th Floor New York, NY 10022 The 5 Columbus Circle Center has 30 fully furnished and wired offices, two conference rooms, and a large pantry / break room serving freshly brewed Starbucks Coffee and a continental breakfast every morning.
    [Show full text]
  • Biotechnology: Answers to Common Questions
    FSR0030 Biotechnology: Answers to Common Questions Kevin Keener, Assistant Professor of Food Science Thomas Hoban, Professor of Sociology and Food Science N.C. Cooperative Extension Service N.C. State University We are entering the “Century of Biology.” Recent developments in the biological sciences are giving us a better understanding of the natural world. At the same type we are developing new tools that are collectively referred to as “biotechnology.” These help us address problems related to human health, food production, and the environment. Any new technology – particularly one as far-reaching as biotechnology – will generate interest, as well as concerns. Because the science behind biotechnology is complex, misconceptions arise over its impacts and implications. In this publication we will answer questions many people have about biotechnology. These questions are organized along the lines of a news story: what, when, who, where, why, and how. We also provide a list of additional information sources available on the Internet. Our primary focus will be on the uses of biotechnology in agriculture and food production since these appear to be more controversial than other applications (at least up until this time). What is Biotechnology? In its broadest sense, biotechnology refers to the use of living systems to develop products. New scientific discoveries are allowing us to better understand fundamental life processes at the cellular and molecular level. Now we can improve selected attributes of microbes, plants, or animals for human use by making precise genetic changes that were not possible with traditional methods. All living organisms contain genes that carry the hereditary traits between generations.
    [Show full text]
  • Potential Opportunities from One of the Fastest Growing Major Global Healthcare Markets1
    KURE 3/31/2018 China Healthcare: Potential Opportunities From One Of The Fastest Growing Major Global Healthcare Markets1 An Overview of the KraneShares MSCI All China Health Care Index ETF (Ticker: KURE) 1. Major healthcare markets defined as top five global markets by the World Health Organization. Data from the World Health Organization as of 12/31/2015. Retrieved 3/31/2018 [email protected] 1 Introduction to KraneShares About KraneShares Krane Funds Advisors, LLC is the investment manager for KraneShares ETFs. Our suite of China focused ETFs provides investors with solutions to capture China’s importance as an essential element of a well-designed investment portfolio. We strive to provide innovative, first to market strategies that have been developed based on our strong partnerships and our deep knowledge of investing. We help investors stay up to date on global market trends and aim to provide meaningful diversification. Krane Funds Advisors, LLC is majority owned by China International Capital Corporation (CICC). 2 Investment Strategy: KURE seeks to measure the performance of MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The KURE securities in the Index include all types of publicly issued shares of Chinese issuers, which are listed in Mainland China, Hong Kong and United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard (GICS) as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies.
    [Show full text]
  • Annual Report
    2020 (Incorporated in Hong Kong with limited liability) (Stock Code : 00656) Annual Report Profit Attributable to Owners of the Parent RMB 8,017.9 million Innovation & Win The year 2020 might be the most challenging year for Fosun, yet it was also the best year. After the pandemic, we continue with the “wartime mechanism” and maintain the fighting spirit that we have developed during the global combat against COVID-19. This has resulted in our resilient business performance throughout the year. The pandemic has also allowed us to refine further our capabilities of the Company accumulated over the years for “Industry Operations + Industrial Investment”, FC2M model, globalization and technology innovation. Fosun has thus evolved and become even stronger. The theme of Fosun’s annual report this year is “Innovation & Win”. “Innovation” means Fosun always attaches great importance to innovation. We recognize that we can create world-class products only by increasing investment in innovation and R&D. It is also because of our investment in technology innovation in various industries over the years, as well as leveraging on Fosun’s diversified and globalized business portfolio, the development model of “Industry Operations + Industrial Investment”, and the “wartime” mode that it has upkept since the battle against the pandemic, that together effectively defended the impact brought by the external environment and brought the Group a resilient performance, thereby creating mutually beneficial and win-win situation to all stakeholders. The year 2021 is a new starting point for Fosun’s transformation. Facing the huge opportunities in the industrial internet era, we will continue to create good products and put the operation of customers (C-end) as our top priority to fully unlock the multiplier growth of good products and customer resources in Fosun’s ecosystem.
    [Show full text]
  • Biontech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine
    BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine January 25, 2021 COMIRNATY® (also known as BNT162b2, Chinese product name: 復必泰TM) is the first COVID-19 vaccine to receive Authorization for Emergency Use in Hong Kong MAINZ, GERMANY, and SHANGHAI, CHINA, January 25, 2021 —BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of the Hong Kong Special Administrative Region of the PRC (“Hong Kong”), the COVID-19 vaccine COMIRNATY® (also known as BNT162b2, Chinese product name: 復必泰TM) based on BioNTech’s proprietary mRNA technology has received authorization for emergency use in Hong Kong. The vaccine will be produced in BioNTech’s manufacturing facilities in Germany and supplied to Hong Kong for administration under the Hong Kong SAR Government’s COVID-19 Vaccination Program. “We are excited and encouraged that COMIRNATY® has been authorized to emergency use in Hong Kong. This is an important milestone in the joint efforts of BioNTech and Fosun Pharma to achieve vaccine accessibility globally. We will continue working closely with BioNTech to complete the ongoing clinical trial and marketing registration in Greater China,” Wu Yifang, Chairman and CEO of Fosun Pharma said. “We will also cooperate closely with HKSAR regarding vaccination deployment plan to ensure that Hong Kong citizens can receive a well-tolerated and effective mRNA COVID-19 vaccine as soon as possible in order to protect the health of millions of households.” On 16 March 2020, BioNTech and Fosun Pharma announced a strategic collaboration to work jointly on the development and commercialization of a COVID-19 vaccine product in Greater China based on BioNTech’s proprietary mRNA technology platform.
    [Show full text]
  • BIO-210 Introduction to Biotechnology
    Bergen Community College Division of Mathematics, Science, and Technology Department of Biology and Horticulture Introduction to Biotechnology (BIO-210) General Course Syllabus Spring 2016 Course Title: BIO-210 Introduction to Biotechnology Course Description: This course is designed to give students both a theoretical background and a working knowledge of the instrumentation and techniques employed in a biotechnology laboratory. Emphasis will be placed on the introduction of foreign DNA into bacterial cells, as well as the analysis of nucleic acids (DNA and RNA) and proteins. Prerequisites: BIO-101 General Biology I General Education Course: No Course Credits 4.0 Hours per week: 6.0: 3 hours lecture and 3 hours lab Course Coordinator: John Smalley Required Textbook: Introduction To Biotechnology, 3rd edition, Thieman, W.J. and M.A. Palladino. Pearson/Benjamin Cummings. Required Lab Manual: None Student Learning Objectives The student will be able to: 1. Students will demonstrate proper scientific laboratory record keeping. Students will be evaluated by periodic notebook collections. 2 Students will be able to explain the scientificbasis for each technique used. Students will be required to answer exam questions designed to allow them to demonstrate their acquisition and retention of this knowledge. 3. Students will learn how to introduce foreign DNA into bacterial cells for the purpose of molecular cloning. Students will be evaluated by observation in the laboratory and analysis of experimental results. Assessment will also be based upon performance on exam questions. 4. Students will be able to retrieve cloned DNA and analyze it using restriction endonuclease digestion and agarose gel electrophoresis. Students will be evaluated by observation in the laboratory and analysis of experimental results.
    [Show full text]
  • Copyrighted Material
    INDEX Aodayixike Qingzhensi Baisha, 683–684 Abacus Museum (Linhai), (Ordaisnki Mosque; Baishui Tai (White Water 507 Kashgar), 334 Terraces), 692–693 Abakh Hoja Mosque (Xiang- Aolinpike Gongyuan (Olym- Baita (Chowan), 775 fei Mu; Kashgar), 333 pic Park; Beijing), 133–134 Bai Ta (White Dagoba) Abercrombie & Kent, 70 Apricot Altar (Xing Tan; Beijing, 134 Academic Travel Abroad, 67 Qufu), 380 Yangzhou, 414 Access America, 51 Aqua Spirit (Hong Kong), 601 Baiyang Gou (White Poplar Accommodations, 75–77 Arch Angel Antiques (Hong Gully), 325 best, 10–11 Kong), 596 Baiyun Guan (White Cloud Acrobatics Architecture, 27–29 Temple; Beijing), 132 Beijing, 144–145 Area and country codes, 806 Bama, 10, 632–638 Guilin, 622 The arts, 25–27 Bama Chang Shou Bo Wu Shanghai, 478 ATMs (automated teller Guan (Longevity Museum), Adventure and Wellness machines), 60, 74 634 Trips, 68 Bamboo Museum and Adventure Center, 70 Gardens (Anji), 491 AIDS, 63 ack Lakes, The (Shicha Hai; Bamboo Temple (Qiongzhu Air pollution, 31 B Beijing), 91 Si; Kunming), 658 Air travel, 51–54 accommodations, 106–108 Bangchui Dao (Dalian), 190 Aitiga’er Qingzhen Si (Idkah bars, 147 Banpo Bowuguan (Banpo Mosque; Kashgar), 333 restaurants, 117–120 Neolithic Village; Xi’an), Ali (Shiquan He), 331 walking tour, 137–140 279 Alien Travel Permit (ATP), 780 Ba Da Guan (Eight Passes; Baoding Shan (Dazu), 727, Altitude sickness, 63, 761 Qingdao), 389 728 Amchog (A’muquhu), 297 Bagua Ting (Pavilion of the Baofeng Hu (Baofeng Lake), American Express, emergency Eight Trigrams; Chengdu), 754 check
    [Show full text]
  • Manhattan Retail Market MID-2ND QUARTER 2016 REPORT Retail Activity in the News
    Manhattan Retail Market MID-2ND QUARTER 2016 REPORT Retail Activity In The News Virtual Restaurant Business Revolutionizing Traditional Food Delivery The growing convenience of home food delivery through services such as Seamless and GrubHub has prompted the launch of what can be best described as “virtual restaurants.” One company Green Summit Group currently operates 2-kitchens and boasts 8 “restaurant” brands, yet is void of any storefronts. The business model is banking on the projection that most New York City dwellers won’t care or realize that the food is not being prepared in a traditional restaurant. Green Summit has eliminated the burden of managing retail spaces, while also further benef ting from its ability to shift menu items more quickly to cater to the fast-evolving preferences of consumers by creating another online-branded “restaurant” that appeals to the f avor of the moment. If a particular brand does not meet f nancial expectations it is easily scrapped, incurring a relatively low cost of failure. Currently in expansion mode, in addition to existing kitchens in Midtown and Williamsburg, Brooklyn, the Green Summit plans to open 4 additional kitchens in the Financial District, Downtown Brooklyn, the Upper East Side, and the East Village in 2016 in order to be within delivery range of 90% of New York’s online food-ordering population according to the company’s projections. Generating about $10 million in revenue in 2015, expansion plans are reportedly expected to triple revenue in 2016. Success of the company launched about 2 and a-half years ago may be short-lived in the opinion of some skeptics of the virtual model, pointing out that consumers want to engage with the restaurant brand.
    [Show full text]
  • Pacer CSOP FTSE China A50 ETF Schedule of Investments July 31, 2020 (Unaudited) Shares Value COMMON STOCKS - 98.0% Agriculture - 1.6% Muyuan Foodstuff Co Ltd
    Page 1 of 4 Pacer CSOP FTSE China A50 ETF Schedule of Investments July 31, 2020 (Unaudited) Shares Value COMMON STOCKS - 98.0% Agriculture - 1.6% Muyuan Foodstuff Co Ltd. - Class A 9,230 $ 120,977 Wens Foodstuffs Group Co Ltd. - Class A 4,660 15,857 136,834 Auto Manufacturers - 0.7% SAIC Motor Corp Ltd. - Class A 24,600 64,077 Banks - 23.7% Agricultural Bank of China Ltd. - Class H 352,300 163,039 Bank of China Ltd. - Class H 193,900 92,512 Bank of Communications Co Ltd. - Class A 184,100 125,556 China CITIC Bank Corp Ltd. - Class H 24,700 18,261 China Construction Bank Corp. - Class H 81,500 71,464 China Everbright Bank Co Ltd. - Class H 126,400 68,456 China Merchants Bank Co Ltd. - Class A 108,200 539,489 China Minsheng Banking Corp Ltd. - Class A 254,300 201,851 Industrial & Commercial Bank of China Ltd. - Class A 198,400 140,993 Industrial Bank Co Ltd. - Class A 127,400 285,849 Ping An Bank Co Ltd. - Class A 75,000 143,348 Shanghai Pudong Development Bank Co Ltd. - Class A 132,300 196,379 2,047,197 Beverages - 17.9% Jiangsu Yanghe Brewery Joint-Stock Co Ltd. - Class A 4,000 77,398 Kweichow Moutai Co Ltd. - Class A 4,000 961,777 Wuliangye Yibin Co Ltd. - Class A 16,200 504,835 1,544,010 Building Materials - 1.6% Anhui Conch Cement Co Ltd. - Class H 15,900 139,921 Coal - 0.5% China Shenhua Energy Co Ltd.
    [Show full text]
  • Ulcerative Colitis
    +44 20 8123 2220 [email protected] Ulcerative Colitis - Pipeline Review, H1 2020 https://marketpublishers.com/r/U44188EFA0EEN.html Date: April 2020 Pages: 671 Price: US$ 2,000.00 (Single User License) ID: U44188EFA0EEN Abstracts Ulcerative Colitis - Pipeline Review, H1 2020 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape. Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids. REPORT HIGHLIGHTS Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected] involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects.
    [Show full text]